Diamyd Medical AB | Cash Flow

Fiscal year is September-August. All values SEK Thousands.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
13,032.00
16,732.00
21,568.00
32,059.00
25,520.00
Depreciation, Depletion & Amortization
155.00
108.00
26.00
106.00
106.00
Other Funds
-
95.00
-
-
-
Funds from Operations
14,386.00
16,014.00
19,291.00
18,396.00
26,101.00
Changes in Working Capital
671.00
676.00
980.00
644.00
293.00
Net Operating Cash Flow
13,715.00
16,690.00
18,311.00
17,752.00
25,808.00
Capital Expenditures
-
130.00
400.00
-
-
Sale of Fixed Assets & Businesses
36,882.00
-
-
-
-
Purchase/Sale of Investments
-
24,015.00
4,045.00
5,665.00
27,885.00
Net Investing Cash Flow
36,882.00
24,145.00
4,445.00
5,665.00
27,885.00
Net Financing Cash Flow
20,386.00
95.00
14,956.00
21,747.00
82,958.00
Net Change in Cash
43,558.00
40,803.00
7,986.00
9,668.00
29,297.00
Free Cash Flow
13,715.00
16,820.00
18,711.00
17,752.00
25,808.00
Change in Capital Stock
20,386.00
-
14,956.00
21,747.00
82,958.00
Exchange Rate Effect
5.00
127.00
186.00
8.00
32.00

About Diamyd Medical AB

View Profile
Address
Kungsgatan 29
Stockholm AB 111 56
Sweden
Employees -
Website http://www.diamyd.com
Updated 09/14/2018
Diamyd Medical AB engages in the development of pharmaceutical products for the treatment of diabetes. It develops vaccine to cure autoimmune diabetes. The firm also involves in investment in medical and stem cell technology.